Bharat Biotech

Bharat Biotech, a renowned Indian biotechnology company, has gained international recognition for its contributions to developing vaccines.

Established in 1996 by Dr Krishna M. Ella and Mrs Suchitra K. Ella, Bharat Biotech has aimed to address critical healthcare challenges and bridge gaps in access to life-saving medical interventions.

Bharat Biotech's foray into vaccine development is primarily due to its world-class research and development capabilities which have led to the creation of several crucial vaccines.

To combat the deadly pandemic, Bharat Biotech swiftly developed Covaxin, an indigenous COVID-19 vaccine. Covaxin's development showcased the company's ability to adapt and respond to emerging health threats. It played a vital role in India's vaccination campaign and contributed to the global fight against the pandemic.

Bharat Biotech's Rotavac became the world's first low-cost oral rotavirus vaccine. This breakthrough marked a significant step in combating a leading cause of severe diarrhoea in children, particularly in low-resource settings.

The company's typhoid conjugate vaccine has been instrumental in reducing the burden of typhoid fever, a major public health concern in many parts of the world.

Bharat Biotech's success is rooted in its cutting-edge research, collaborative partnerships, and affordability and accessibility. The company's vaccines have been exported to numerous countries, playing a crucial role in improving health outcomes and preventing diseases on a global scale.